ES2117046T3 - Anticuerpo anti-factor de crecimiento en el tratamiento de estenosis vascular. - Google Patents

Anticuerpo anti-factor de crecimiento en el tratamiento de estenosis vascular.

Info

Publication number
ES2117046T3
ES2117046T3 ES92905617T ES92905617T ES2117046T3 ES 2117046 T3 ES2117046 T3 ES 2117046T3 ES 92905617 T ES92905617 T ES 92905617T ES 92905617 T ES92905617 T ES 92905617T ES 2117046 T3 ES2117046 T3 ES 2117046T3
Authority
ES
Spain
Prior art keywords
growth factor
treatment
vascular stenosis
antibody anti
stenosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92905617T
Other languages
English (en)
Inventor
Russell Ross
Michael A Reidy
Elaine W Raines
Volkhard Lindner
Gordon A A Ferns
Christopher Jackson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Application granted granted Critical
Publication of ES2117046T3 publication Critical patent/ES2117046T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

METODOS PARA INHIBIR LA ESTENOSIS VASCULAR EN UN MAMIFERO, INCLUYENDO LA ESTENOSIS QUE SIGUE A UNA EXTIRPACION QUIRURGICA DE PLACAS ARTEROESCLEROTICAS O BY OCLUIDAS. LA INHIBICION SE CONSIGUE A TRAVES DE LA ADMINISTRACION DE ANTICUERPOS DEL FACTOR DE ANTI-CRECIMIENTO, INCLUYENDO ANTICUERPOS ANTI-FGF Y ANTICUERPOS ANTI-PDGF.
ES92905617T 1991-01-17 1992-01-17 Anticuerpo anti-factor de crecimiento en el tratamiento de estenosis vascular. Expired - Lifetime ES2117046T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64175891A 1991-01-17 1991-01-17

Publications (1)

Publication Number Publication Date
ES2117046T3 true ES2117046T3 (es) 1998-08-01

Family

ID=24573729

Family Applications (2)

Application Number Title Priority Date Filing Date
ES97106298T Expired - Lifetime ES2174144T3 (es) 1991-01-17 1992-01-17 Anticuerpos contra el factor de crecimiento derivado de plaquetas en el tratamiento de la reestenosis.
ES92905617T Expired - Lifetime ES2117046T3 (es) 1991-01-17 1992-01-17 Anticuerpo anti-factor de crecimiento en el tratamiento de estenosis vascular.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES97106298T Expired - Lifetime ES2174144T3 (es) 1991-01-17 1992-01-17 Anticuerpos contra el factor de crecimiento derivado de plaquetas en el tratamiento de la reestenosis.

Country Status (10)

Country Link
US (1) US5648076A (es)
EP (2) EP0798002B1 (es)
JP (2) JP3667752B2 (es)
AT (2) ATE164521T1 (es)
AU (1) AU665529B2 (es)
CA (1) CA2100876A1 (es)
DE (2) DE69224983T2 (es)
DK (2) DK0573510T3 (es)
ES (2) ES2174144T3 (es)
WO (1) WO1992012734A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770198A (en) * 1988-05-18 1998-06-23 The Research Foundation Of The State Of New York Platelet-specific chimeric 7E3 immunoglobulin
CN1186439A (zh) * 1995-06-07 1998-07-01 森特克公司 血小板特异性的嵌合性免疫球蛋白及其使用方法
US7241568B2 (en) 1996-04-03 2007-07-10 Kyowa Hakko Kogyo Co., Ltd. Anti-fibroblast growth factor-8 monoclonal antibody
AU6497198A (en) * 1997-02-14 1998-09-08 Boehringer Mannheim Gmbh Improved method for the reduction of neointima formation after angioplasty
EP1422243B1 (en) * 2001-06-28 2008-04-23 Kyowa Hakko Kogyo Co., Ltd Humanized antibody against fibroblast growth factor-8 and fragment of the antibody
PL1680140T3 (pl) * 2003-10-16 2011-11-30 Imclone Llc Inhibitory receptora-1 czynnika wzrostu fibroblastów i związane z nim sposoby leczenia
US9339593B2 (en) * 2007-01-11 2016-05-17 Robert L. Bjork, JR. Drug-eluting coronary artery stent coated with anti-platelet-derived growth factor antibodies overlaying extracellular matrix proteins with an outer coating of anti-inflammatory (calcineurin inhibitor) and/or anti-proliferatives
JP5602432B2 (ja) * 2007-01-11 2014-10-08 ロバート ラマール ジュニア ビョーク 経皮的冠動脈インターベンション用の多剤溶出冠動脈ステント
WO2016149103A1 (en) * 2015-03-13 2016-09-22 The Regents Of The University Of California Monoclonal antibody for prevention and/or treatment of astrovirus disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE116373T1 (de) * 1987-03-03 1995-01-15 Takeda Chemical Industries Ltd Monoklonaler antikörper, hybridomen, ihre herstellung und ihre verwendung.
CA1339356C (en) * 1988-02-02 1997-08-26 Lewis T. Williams Human platelet-derived growth factor receptor
US5268358A (en) * 1988-12-08 1993-12-07 Cor Therapeutics, Inc. PDGF receptor blocking peptides
AU6605690A (en) * 1989-10-27 1991-05-31 Du Pont Merck Pharmaceutical Company, The Monoclonal antibodies to basic fibroblast growth factor that inhibit its biological activity
JP4350370B2 (ja) * 2002-12-27 2009-10-21 株式会社半導体エネルギー研究所 電子回路及び電子機器

Also Published As

Publication number Publication date
WO1992012734A1 (en) 1992-08-06
DE69232579T2 (de) 2002-08-22
JP3667752B2 (ja) 2005-07-06
EP0573510B1 (en) 1998-04-01
DE69224983D1 (de) 1998-05-07
AU1327492A (en) 1992-08-27
EP0573510A1 (en) 1993-12-15
DE69232579D1 (de) 2002-05-29
DE69224983T2 (de) 1998-07-30
ATE216592T1 (de) 2002-05-15
ATE164521T1 (de) 1998-04-15
ES2174144T3 (es) 2002-11-01
DK0573510T3 (da) 1998-04-27
DK0798002T3 (da) 2002-08-19
JPH06504551A (ja) 1994-05-26
CA2100876A1 (en) 1992-07-18
EP0798002A1 (en) 1997-10-01
JP2002316945A (ja) 2002-10-31
EP0798002B1 (en) 2002-04-24
US5648076A (en) 1997-07-15
AU665529B2 (en) 1996-01-11

Similar Documents

Publication Publication Date Title
DE69312077T2 (de) Behandlung von autoimmun- und entzundungskrankheiten
FI946004A0 (fi) Lääketieteellisessä toimenpiteessä käytettävä trombiiniverifraktio
PT646012E (pt) Cura de feridas e tratamento de perturbacoes fibroticas por tgfbeta-3
AR005535A1 (es) El uso de anticuerpos anti-cd18 para la manufactura de un medicamento para tratar ataques focales isquemicos, articulo de manufactura y equipo que loscomprenden
ATE186460T1 (de) Methode zur verhinderung von restenosierung nach rekanalisierung von körpergefässen
DE59108854D1 (de) Arzneimittel sowie deren herstellung und deren verwendung bei der bekämpfung von schmerzen und/oder entzündungen an tieren und menschen
AR002254A1 (es) Formulacion antitrombotica y procedimiento para su manufactura
NO920946D0 (no) Oral antikoagulant/blodplateinhibitor i lavdoseformulering
ES2117046T3 (es) Anticuerpo anti-factor de crecimiento en el tratamiento de estenosis vascular.
NO894222L (no) Fremgangsmaater for behandling og profylakse av pneumocytis carinii pneumoni og andre sykdommer og forbindelser og formuleringer for anvendelse i nevnte metoder.
LU88442A1 (fr) Association synergisante ayant un effet antagoniste des récepteurs NK1 et NK2
DE58906239D1 (de) Einrichtung zur Behandlung von Erkrankungen, insbesondere der Sehbahn.
ES2055314T3 (es) Tratamiento de disfuncion leucocitaria con gm-csf.
ES2124765T3 (es) N-acil derivados de hidroxiaminas que tienen actividad eliminadora y que son utiles en patologias agudas y cronicas asociadas con los fenomenos de peroxidacion e inflamacion.
Belzer et al. Ex vivo renal artery reconstruction with autotransplantation
MX9206135A (es) Metodos
DE59002185D1 (de) Kombinationspraeparat mit antithrombotischer wirkung.
ES2087765T3 (es) Uso del ajo silvestre para la terapia o profilaxis de trastornos del ritmo cardiaco.
DK0471660T3 (da) Protein C til behandling af smerte
SE9303612D0 (sv) New use
ES2087764T3 (es) Uso del ajo de oso en el tratamiento o prevencion de los trastornos circulatorios.
ATE107166T1 (de) Verwendung von chlormethiazol zur herstellung eines artzneimittels zur prophylaxe oder therapie der neurodegeneration.
SE8802040D0 (sv) New use
DE69201975T2 (de) Pyrimido-benzothiazinderivate zur Behandlung von Entzündung, Allergie and kardiovaskulären Erkrankung.
OZAKI et al. A case of non-anastomotic aneurysm of Dacron graft

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 573510

Country of ref document: ES